NAVIGATOR Data Published in New England Journal of Medicine, and Latest Data from Tezepelumab Clinical Program Presented at ATS 2021 International Conference
Tezepelumab Reduced Exacerbations by 77% in Subgroup of Patients with Elevated Inflammatory Biomarkers in NAVIGATOR
Tezepelumab Reduced Exacerbations Requiring Hospitalization by 85%
PR Newswire
THOUSAND OAKS, Calif., May 13, 2021